CN104042625A - Application of sodium bicarbonate in puerarin injection - Google Patents
Application of sodium bicarbonate in puerarin injection Download PDFInfo
- Publication number
- CN104042625A CN104042625A CN201410248192.8A CN201410248192A CN104042625A CN 104042625 A CN104042625 A CN 104042625A CN 201410248192 A CN201410248192 A CN 201410248192A CN 104042625 A CN104042625 A CN 104042625A
- Authority
- CN
- China
- Prior art keywords
- injection
- puerarin
- sodium bicarbonate
- application
- transfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an application of sodium bicarbonate in puerarin injection. According to the injection, sodium bicarbonate and puerarin are prepared into the injection containing puerarin, or sodium bicarbonate and puerarin are applied together in the puerarin injection, sporadic hemolysis adverse reaction of injection containing puerarin is effectively overcome, and the security of puerarin injection administration is improved.
Description
Technical field
The present invention relates to the new medical use of sodium bicarbonate, be specifically related to the application in puerarin injection.
Background technology
Sodium bicarbonate has another name called sodium bicarbonate, molecular formula NaHCO
3, molecular weight 84, is the alkaline medicine of commonly using clinically, clinical practice is wider.Along with the development of medicinal career, the novel clinical use of sodium bicarbonate is more and more, comprises following aspect: treatment thrombotic disease.After the quiet note of sodium bicarbonate, can discharge in vivo CO
2, improve CO in blood
2concentration, reflexive ground blood vessel dilating, increase blood flow, therefore be used for treating thrombotic disease.Treatment status asthmaticus and ASP.Severe Asthma persistent state patient to 4 examples through failing of the effect with Comprehensive Treatment, after sodium bicarbonate treatment, all obtains remarkable result.Status asthmaticus is associated with acidosis mostly, now trachea is suppressed epinephrine reactivity, increase the release of anaphylaxis medium, cause irritated individual asthma aggravation, and sodium bicarbonate can be removed this inhibitory action, make the reactivity of body recovery to bronchiectasis medicine, reach the effect of removing bronchospasm.Treatment lumbago and skelalgia, intractable, vascular headache.It is generally acknowledged that the slight blood stasis of vascular headache and cerebral tissue, weary oxygen, acidic metabolite increase, cerebrovascular shrink function imbalance is relevant, sodium bicarbonate can make the cerebrovascular in diastole state shrink, and also can make the intracranial vessel expansion in spasticity, maintains vasomotoricity balance.Treatment fungal enteritis.Someone reports that mycete Growth and reproduction under sour environment is active, suppresses its numerous value of growing in alkaline environment.Treat intractable chronic nephritis.Insensitive various chronic nephritis 18 examples such as ordered pair hormone are controlled in sodium bicarbonate intravenous drip.Result is alleviated 12 examples substantially; Partial rcsponse 5 examples.Treatment vertigo, the infringement for the treatment of streptomycin to cranial nerve.Due to streptomycin poisoning, the report of the 8th pair of cranial nerve lesions is a lot of, and cardinal symptom has headache, dizzy, tinnitus, feels sick, auditory dysesthesia, bulge of the ear, ataxia etc.After the quiet note treatment of application sodium bicarbonate, all dizzy after medication, tinnitus, the symptom such as feel sick all disappear and (see the novel clinical use > > of the < < sodium bicarbonate that Liu Jiasheng writes 7 examples as a result, Journal of Chinese Hospital Pharmacy, 1989,9 (9): 395-397 page).
Sodium bicarbonate also has other a lot of purposes, as slow down aging, alkalized urine, prevent sulfanilamide crystallization in urine, treatment metabolic acidosis, shock, hyperkalemia, cardio-pulmonary resuscitation, heart failure, pulmonary edema, hypercapnia etc. (are shown in the novel clinical use > > of the < < sodium bicarbonate that Jie newly writes, foreign medical science (hospital management fascicle), 2002,3:28 page).
Puerarin is monomer one isoflavone compounds extracting from the dry root of legume pueraria lobata, 4 ', and 7 one dihydroxy-8-β-D glucone isoflavone.Be widely used in clinically the treatment of cardiovascular disease.Being applied at present the clinical pharmaceutical preparation that contains puerarin is mainly injection.Along with being widely used of puerarin, the report of relevant puerarin untoward reaction is also more and more in recent years, causes the world of medicine's extensive concern.By analyzing nearly 20 years adverse reaction of tcm, puerarin injection ranks the 18th.The untoward reaction of puerarin injection had once been circulated a notice of at national drug adverse reaction monitoring center in phase < < adverse drug reaction communication > > January the 3rd in 2003.Most researchers is thought, puerarin injection be take 50% propylene glycol as solvent formulated, unavoidably because the difference generation purity of the aspects such as extraction process, technology is inadequate, introduce impurity and cause various reactions (to see that the analysis > > of untoward reaction appears in the < < that Xu Xianghui writes to clinical use puerarin injection, journal of shanghai Chinese medicine, 2006,40 (8): 71-72; The clinical practice of the < < puerarin that He Xu generation state writes and untoward reaction > >, time precious traditional Chinese medical science traditional Chinese medicines, 2005,16 (12): 1307-1308).After analyzing, 63 routine puerarin untoward reaction of the domestic main medical journals of Chinese report to 2000-2004 find male 40 examples, female's 23 examples; Year at age 34～81 (57.5 ± 23.5).All cases are intravenous drip administration.Dosage is 0.4～0.6g, and medicine diluent is 5% Glucose Liquid, normal saline, 5% glucose saline etc.The fastest person of reacting generating time is 3min, and the slowest person is 13d, all occurs in administration process.There are responder 47 examples in first administration, responder 16 examples appear in repeat administration.Statistics shows, common adverse reactions has allergy (generate heat, tremble etc., 24 examples), anaphylactic shock (4 example), hemolytic anemia (13 example), hepatic injury, renal damage (7 example), drug fever (10 example), dead (5 example).All cases are all without allergies, and after reaction occurs, drug withdrawal all recovers (except death) through anti symptom treatment.Dosage and used diluent are in package insert prompting range, and institute responds all certainly as due to puerarin.The generation of untoward reaction and suffer from disease independent, have nothing to do with age, sex, contacts without much with drug dilution liquid.Relevant with patient's body constitution difference, particularly elderly and infirm easily occurs.The length of reacting generating time is relevant with the slow degree of Chinese medicine preparation onset (sees the flourish routine document analysis > > of < < puerarin untoward reaction 63 writing whole-heartedly, modern combination of Chinese and Western medicine magazine, 2005,14 (1): 140).Quiet about 10min of puerarin of one patient, appear as acute renal insufficiency, hemolytic anemia (is shown in the < < Puerarin and hemolytic anemia > > that Guan Minghua writes, adverse effect magazine, 2003,5:291).Therefore the hemolytic anemia that, puerarin causes is due to puerarin itself.
Summary of the invention
The object of the present invention is to provide the new medical use of sodium bicarbonate, i.e. the application of sodium bicarbonate in puerarin injection, sodium bicarbonate can effectively be prevented and treated the intravascular hemolysis untoward reaction that puerarin brings out.
In fact, the present invention relates to the application of sodium bicarbonate when preparing puerarin injection with compound preparation, also can with puerarin injection with injection and transfusion the interim fit applications of mode, or with injection and transfusion mode application sodium bicarbonate after then apply again puerarin injection.
For achieving the above object, the technical solution used in the present invention is: sodium bicarbonate is being prepared the new purposes of puerarin injection.Sodium bicarbonate and puerarin injection are with the interim fit applications of mode of injection and transfusion.After the mode application sodium bicarbonate with injection and transfusion, then apply again puerarin injection.
Related content in technique scheme is explained as follows:
1,, in such scheme, described injection, contains following weight portion medicine: 1～100 part of sodium bicarbonate, 1～100 part of puerarin.
2,, in such scheme, described injection, also contains adjuvant 1～50 weight portion, water for injection 1～10000 weight portion.Described adjuvant is Glucose Liquid, propylene glycol liquid, glucose saline, sodium chloride injection or normal saline.
3,, in such scheme, described injection can be acceptable injection, powder pin or transfusion clinically.
4,, in such scheme, the preparation method of described injection is as described below:
Described powder pin, is made by sodium bicarbonate and puerarin mixing, sterilizing; Or by sodium bicarbonate, puerarin and sodium chloride, mixed, be dissolved in water for injection, then adjust pH value to 5.0-8.5 with hydrochloric acid or sodium hydroxide solution, filter, after filtrate sterilizing, be potted in powdery ampoule sterilizing again and make;
Described injection.By sodium bicarbonate, puerarin and sodium chloride, mixed, be dissolved in water for injection, then adjust pH value 5.0-8.5 with hydrochloric acid or sodium hydroxide solution, filter, filtrate is potted in sterilizing in ampoule and makes.Or sodium bicarbonate is by 5% Glucose Liquid, 5% glucose saline, propylene glycol liquid (is formed by propylene glycol and normal saline (1: 1) configuration by volume, include propylene glycol 0.5mL/mL), sodium chloride injection or physiological saline solution, mix with puerarin injection, filter, filtrate is potted in sterilizing in ampoule and makes.
Described transfusion, is mixed by sodium bicarbonate, puerarin and sodium chloride, is dissolved in water for injection, then adjusts pH value 5.0-8.5 with hydrochloric acid or sodium hydroxide solution, dissolves, and filters, and filtrate is potted in sterilizing in saline vial and makes.Or sodium bicarbonate is by 5% Glucose Liquid, 5% glucose saline, propylene glycol liquid (is formed by propylene glycol and normal saline (1: 1) configuration by volume, include propylene glycol 0.5mL/mL), sodium chloride injection or physiological saline solution, mix with puerarin injection, filter, filtrate is potted in sterilizing in ampoule and makes.
5,, in such scheme, described interim fit applications refers in hospital, mixes together transfusion or injection in application puerarin injection with sodium bicarbonate.
6, in such scheme, described then applies puerarin injection after the mode application sodium bicarbonate with injection and transfusion again, refer in hospital, after the mode application sodium bicarbonate of injecting and infusing, then follow the mode application puerarin injection with injection and transfusion.
Puerarin has and has coronary artery dilator and cerebrovascular, reduction myocardial oxygen consumption, improves the effect of microcirculation and antiplatelet aggregation.Clinically for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, retina arteriovenous obstruction, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.Puerarin can also be made compound puerarin injection for preventing and treating various diseases with sodium bicarbonate compatibility, as for preventing and treating diabetic peripheral neuropathy, hypertension complicated with diabetes mellitus, diabetic nephropathy, acute cerebral infarction, stable angina pectoris, Lower extremity deep venous thrombosis and vertigo due to vertebrobasilar insufficiency etc.But, containing the puerarin in puerarin injection, very easily cause intravascular hemolysis.Sodium bicarbonate has biological effect widely, and present inventor, through studies confirm that sodium bicarbonate also has the intravascular hemolysis untoward reaction that antagonism is brought out by puerarin, improves the safety of puerarin injection administration.
Below in conjunction with the furthermore bright objects of the present invention of some tests and the effect that can reach.
Technological guidance's principle > > of this laboratory reference < < Chinese medicine, natural drug zest and hemolytic research carries out trial test to hemolytic test, find that 8mM puerarin can cause 1% sheep red blood cell (SRBC) haemolysis 10%, external hemolytic test probability of happening is 100%, hemolytic test result is all reappeared, and illustration method can repeat.The method can be used for finding the potential accidental haemolysis of injection, is to carry out the feasible test method that injection new drug development judges whether to exist sporadic haemolysis, is conducive to reduce the generation of untoward reaction, improves the safety of injection.
Effect and the effect of the injection haemolysis untoward reaction that, sodium bicarbonate antagonism contains puerarin
(1) puerarin injection hemolytic test
Research sodium bicarbonate and puerarin share the impact on sheep red blood cell (SRBC).Get the erythrocyte of the cold sheep of 10 little tails, the sodium bicarbonate and the puerarin that add respectively doses, after 10min, observe erythrocytic state and haemolysis incidence rate, with X2 inspection statistics, analyze experimental result, seek the antagonism of sodium bicarbonate to the sporadic haemolysis of puerarin injection.Now that report the test is as follows:
1 experiment material
1.1 tested medicines
1., sodium bicarbonate is provided by Tianjin Kermel Chemical Reagent Co., Ltd. sodium bicarbonate injection, with electronic balance, accurately takes sodium bicarbonate 3.36g, be dissolved in normal saline solution, with 10mL volumetric flask, sodium bicarbonate solution is settled to 10mL, this be injection 1., concentration is 4molL
-1.With microporous filter membrane (0.22 μ m) filtration sterilization, 4 ℃ save backup.
Injection is 2.: with sterile saline, 1. injection is diluted to 2molL
-1, 10mL, 4 ℃ save backup.
Injection is 3.: with sterile saline, 1. injection is diluted to 1molL
-1, 10mL, 4 ℃ save backup.
Puerarin injection is 4.: by Kang Enbei Zhejiang Pharmaceutical Co, provided, and 2mL, batch number 090501, every mL injection is containing puerarin 50mg.
Puerarin injection (250mM) is 5.: with electronic balance, accurately take puerarin powder (purchased from Jiangsu Tian Sheng medicine company limited) 1.041g, with 40% dimethyl sulfoxide (DMSO, DZ0231, AMRESCO) dissolve, ultrasonic dissolution assisting, normal saline solution is diluted to 9mL, and volumetric flask is settled to 10mL, and solution colour is colourless (configuration surroundings: carry out in superclean bench).Solvent is 40%DMSO solution.With microporous filter membrane (0.22 μ m) filtration sterilization, 4 ℃ of preservations.
Compound puerarin injection is 6.: get 1. 0.04mL of injection, injection is 0.27mL 4., mixes, and 6. 0.31mL, form injection altogether.Every mL injection is containing puerarin 43.55mg, sodium bicarbonate 43.35mg.
Compound puerarin injection is 7.: get 2. 0.04mL of injection, injection is 0.27mL 4., mixes, and 7. 0.31mL, form injection altogether.Every mL injection is containing puerarin 43.55mg, sodium bicarbonate 21.68mg.
Compound puerarin injection is 8.: get 3. 0.04mL of injection, injection is 0.27mL 4., mixes, and 8. 0.31mL, form injection altogether.Every mL injection is containing puerarin 43.55mg, sodium bicarbonate 10.84mg.
Compound puerarin injection is 9.: get 1. 0.04mL of injection, injection is 0.13mL 5., mixes, and 9. 0.17mL, form injection altogether.Every mL injection is containing puerarin 79.61mg, sodium bicarbonate 79.06mg.
Compound puerarin injection is 10.: get 2. 0.04mL of injection, injection is 0.13mL 5., mixes, and 10. 0.17mL, form injection altogether.Every mL injection is containing puerarin 79.61mg, sodium bicarbonate 39.53mg.
Compound puerarin injection
: get 3. 0.04mL of injection, injection is 0.13mL 5., mixes, and 0.17mL, forms injection altogether
.Every mL injection is containing puerarin 79.61mg, sodium bicarbonate 19.76mg.
1.2 laboratory animal
Little tail 10 of the sheep (20～30Kg) that tremble with fear, are provided by Xibei Univ. of Agricultural & Forest Science & Technology's zoopery center.15～25 ℃ of room temperatures, under relative humidity 50% condition, raise.
1.3 reagent, instrument
Chloride injection agent, lot number: 31213042402, Shiyao Yinhu Pharmaceutical Co., Ltd. produces; Water for injection, self-control; TGL-16B high speed centrifuge, Hunan Xingke Scientific Instrument Co., Ltd.; HPY-01B biochemical cultivation case, Huangshi Hengfeng Medical Devices Co., Ltd.; BIO-RAD680 microplate reader; Enzyme mark bar is purchased by Haimen, Jiangsu San Hexingya medical apparatus and instruments factory and is produced, purchased from Shaanxi Province Yang Ling Bao Xin equipment company limited.
2 methods
The preparation of 2.1 red blood cell suspensions
10 of the cold sheep of little tail, carry out respectively hemolytic experiment.Every sheep is adopted jugular vein blood 10ml, after heparin sodium (Jiangsu Wanbang Biological Pharmaceutical Co., Ltd.) 160IU anticoagulant, is placed in graduated centrifuge tube, centrifugal 10 minutes with 2000 revs/min, discard blood plasma, add appropriate chloride injection agent washing, centrifugal abandoning supernatant and leukocytic cream.Add again appropriate normal saline shake up, centrifugal, so cyclic washing is 3 times, till being water white transparency to centrifugal rear supernatant.Gained packed red cells is become to the red cell suspension of 11% (volume ratio) with normal saline dilution.So far, red cell suspension is ready.
The outer hemolytic experiment design of 2.2 puerarin solution bodies
If puerarin solution effects is 8mM (0.00333gmL in erythrocytic concentration
-1).If negative control group, solvent control group (replacing puerarin solution effects in erythrocyte with DMSO), drug treating group and positive controls.The pH value of measuring puerarin solution with the desk-top pH meter of METTLER TOLEDO is 7.16.
Shown in following table 1, in test tube, add corresponding composition respectively, note application of sample order.Often add after a kind of composition, all shake up gently.After all adding in system etc. all the components in system, light shaking mixes, and places the biochemical cultivation case incubation of 37 ℃.After 10min, observe haemolysis and aggregation.Aggregation decision method: if having rufous or brownish red flocculent deposit in solution, not disperseing after jolting, show to have red cell agglutination to occur, if can be uniformly dispersed again after condensation product jolting, is pseudoagglutination, is true coagulation if condensation product does not shake loose person.Then each pipe is centrifugal according to 5000rpm/min condition, perusal supernatant fluid color.Get supernatant, in 540nm wavelength place, detect absorbance value (OD value).Technological guidance's principle > > according to < < Chinese medicine, natural drug zest and hemolytic research in 2005, calculates the hemolysis rate (%) of respectively organizing each pipe by formula:
Hemolysis rate (%)=(drug treating group OD value-negative control group OD value)/(positive control pipe group OD value-negative control group OD value)
With reference to evaluation criterion: hemolysis rate > 5%, show to have haemolysis to occur, and carry out statistical procedures.
The external hemolytic experiment packet design of table 1 puerarin solution and sodium bicarbonate
3 results
This test is investigated when puerarin 8mM concentration, and compound puerarin injection sporadic hemolytic experiment research 4., is 5. carried out in 40mM, 20mM, the impact of 10mM sodium bicarbonate on 10 sheep red blood cells simultaneously, and experimental result all has itemized record, uses X
2inspection statistics is analyzed, and the results are shown in Table 2.
10 sheep hemolytic test result statistical tables of table 2
Note: compare a P < 0.01 with the negative group of normal saline; With the comparison of puerarin injection group, b P < 0.01
Result shows: haemolysis does not appear in normal saline group, the whole haemolysis of water for injection group: with the comparison of normal saline group, puerarin injection 4., 5. group all occurs that haemolysis, haemolysis incidence rate and normal saline group exist utmost point significant difference (P < 0.01); Hemolytic test result is all reappeared, and illustrates that this hemolytic experiment method is reliable and stable, and result of the test can repeat.With puerarin injection 4., 5. group relatively, compound puerarin injection 6., 7., 8., 9., 10.,
all there is not haemolysis in each group, compound puerarin injection 6., 7., 8., 9., 10.,
each organize haemolysis incidence rate all with puerarin injection 4., there is utmost point significant difference (P < 0.01) in group 5.; With the comparison of normal saline group, compound puerarin injection 6., 7., 8., 9., 10.,
each organize haemolysis incidence rate all with normal saline group zero difference (P > 0.05); Compound puerarin injection 6., 7., 8., 9., 10.,
4., 5. to organize puerarin concentration identical with puerarin injection for each group, is 8mM, but compound puerarin injection 6. and 9., 7. and 10., 8. and
contain respectively 40mM, 20mM, 10mM sodium bicarbonate, and 4., 5. puerarin injection is respectively organized and is not contained sodium bicarbonate.Above results suggest: the application of the sodium bicarbonate of variable concentrations and puerarin compatibility, the haemolysis untoward reaction of all can antagonism being brought out by puerarin, and can make incidence rate be reduced to normal saline level.
Above experimental result shows: puerarin can cause haemolysis, and the injection that closes puerarin all likely causes haemolysis, after adding sodium bicarbonate, all can eliminate the haemolysis untoward reaction containing puerarin.
Above-mentioned result of the test prompting: the injection that puerarin injection and puerarin and sodium bicarbonate compatibility are made has no the generation of hemolytic reaction.
Therefore, when preparation contains the injection of puerarin or while applying puerarin injection, add sodium bicarbonate, can eliminate the haemolysis untoward reaction that puerarin causes, improved the safety of puerarin injection administration.
Advantage of the present invention is: when preparation contains the injection of puerarin or while applying puerarin injection, adds sodium bicarbonate, there is the intravascular hemolysis untoward reaction that good antagonism is brought out by puerarin, and inexpensive, have no side effect, safety.
Below in conjunction with embodiment, the invention will be further described:
The specific embodiment
The preparation of embodiment 1:(compound puerarin injection)
Get sodium bicarbonate 16.8g, puerarin 10g, adds sodium chloride 9g, adds water to 1000mL, with 1mol/l hydrochloric acid or sodium hydroxide solution, adjusts pH to 5.0-8.5, filter, filtrate be potted in 2,5 or the ampoule of 10mL in, 100 ℃ of sterilizing 30min, obtain injection.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.This product can intravenous injection or intramuscular injection, each 1～500mL, and 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
The preparation of embodiment 2:(compound puerarin powder pin)
Get sodium bicarbonate 33.6g, puerarin 1g, is potted in the powder pin ampoule of 10mL, and 100 ℃ of sterilizing 30min, obtain powder pin.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.During application, will make powder pin 1～5000mg and sodium chloride injection or normal saline solution and mix, can carry out intravenous injection or intramuscular injection, each 1～500mL, 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
The preparation of embodiment 3:(compound puerarin transfusion)
Get sodium bicarbonate 8.4g, puerarin 2g, sodium chloride 9g, adds water to 1000mL, with 1mol/L hydrochloric acid or sodium hydroxide solution, adjusts pH to 5.0-8.5, filters, and filtrate is potted in the saline vial of 250ml, and 100 ℃ of sterilizing 30min, are infused.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.During application, can directly carry out intravenous injection or intramuscular injection, each 1～500mL, 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
Above-described embodiment is only explanation technical conceive of the present invention and feature, and its object is to allow person skilled in the art can understand content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences that spirit is done according to the present invention change or modify, within all should being encompassed in protection scope of the present invention.
Claims (8)
1. the application of sodium bicarbonate in puerarin injection.
2. application according to claim 1, it is characterized in that: sodium bicarbonate can be made compound injection with puerarin injection and use, also can with interim the cooperation simultaneously of mode of injection and transfusion, use with puerarin injection, or then apply again puerarin injection after the mode application sodium bicarbonate with injection and transfusion.
3. application simultaneously according to claim 2, is characterized in that: puerarin injection and sodium bicarbonate injection mix before for patient's application, then applies in the mode of injection and transfusion.
4. after the mode application sodium bicarbonate with injection and transfusion according to claim 2, then apply again puerarin injection, it is characterized in that: first for after patient applies sodium bicarbonate injection and finish, more then apply puerarin injection.
5. according to the injection described in claim 1,2,3,4 and the application of injection, it is characterized in that: contain following weight portion medicine: 1～100 part of sodium bicarbonate, 1～100 part of puerarin.
6. according to the injection described in claim 1,2,3,4,5 and the application of injection, it is characterized in that: can contain adjuvant 1～50 weight portion, water for injection 1～10000 weight portion.
7. according to the injection described in claim 1,2,3,4,5,6 and the application of injection, it is characterized in that: described adjuvant can be Glucose Liquid, glucose saline, propylene glycol liquid, sodium chloride injection or normal saline solution.
8. according to the injection described in claim 1,2,3,4,5,6 or 7 and the application of injection, it is characterized in that: described injection and the application of injection can be acceptable injection, powder pin or transfusion clinically.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410248192.8A CN104042625A (en) | 2014-05-28 | 2014-05-28 | Application of sodium bicarbonate in puerarin injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410248192.8A CN104042625A (en) | 2014-05-28 | 2014-05-28 | Application of sodium bicarbonate in puerarin injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042625A true CN104042625A (en) | 2014-09-17 |
Family
ID=51496350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410248192.8A Pending CN104042625A (en) | 2014-05-28 | 2014-05-28 | Application of sodium bicarbonate in puerarin injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042625A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112516125A (en) * | 2020-12-23 | 2021-03-19 | 西北农林科技大学 | Application of tyrosine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| WO2022183055A1 (en) * | 2021-02-26 | 2022-09-01 | Nevakar Injectables Inc. | Sodium bicarbonate injectable formulation and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242217A (en) * | 1998-07-17 | 2000-01-26 | 烟台绿叶制药有限公司 | Traditional Chinese medicine compositions contg. pueraria root extract |
-
2014
- 2014-05-28 CN CN201410248192.8A patent/CN104042625A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242217A (en) * | 1998-07-17 | 2000-01-26 | 烟台绿叶制药有限公司 | Traditional Chinese medicine compositions contg. pueraria root extract |
Non-Patent Citations (1)
| Title |
|---|
| FEI CHEN，SHANGQIN LIU ，JIANG WU: "Puerarin-induced immune hemolytic anemia", 《THE JAPANESE SOCIETY OF HEMATOLOGY》, vol. 98, no. 1, 10 May 2013 (2013-05-10) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112516125A (en) * | 2020-12-23 | 2021-03-19 | 西北农林科技大学 | Application of tyrosine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| CN112516125B (en) * | 2020-12-23 | 2024-03-15 | 西北农林科技大学 | Application of tyrosine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| WO2022183055A1 (en) * | 2021-02-26 | 2022-09-01 | Nevakar Injectables Inc. | Sodium bicarbonate injectable formulation and methods of use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102160852A (en) | Ibuprofen injection and preparation method thereof | |
| CN104042625A (en) | Application of sodium bicarbonate in puerarin injection | |
| CN103054883B (en) | Medicine composition containing fructose sodium diphosphate compound | |
| CN105641004A (en) | Traditional Chinese medicine composition formed by ginkgo biloba extract and application thereof to preparation of Shuxuening parenteral solution | |
| CN104055763B (en) | Application of the glycine on the drug for preparing the intravascular hemolysis that prevention puerarin injection induces | |
| RU2011141457A (en) | PLASMA ADAPTED BALANCED ELECTROLYTE SOLUTION | |
| CN105287370B (en) | A kind of preparation method of inosine and combinations thereof composition injection | |
| CN104042603A (en) | Applications of gamma-aminobutyric acid in puerarin injection | |
| CN108553413A (en) | Injection esomeprazole sodium | |
| CN104606130B (en) | A kind of Tropisetron HCl parenteral solution and preparation method thereof | |
| CN104042602A (en) | Application of sodium glutamate in puerarin injection | |
| CN102397281B (en) | Ginsenoside composition for treating cardiovascular and cerebrovascular diseases | |
| CN103933061A (en) | Application of calcium chloride in puerarin injection | |
| CN104013613A (en) | Application of vitamin E in puerarin injection | |
| CN106214692A (en) | The application of peoniflorin 6 O ' benzene sulfonate treatment hepatic fibrosis and confirmatory experiment method | |
| CN104013615A (en) | Application of vitamin C in puerarin injection | |
| CN112516125B (en) | Application of tyrosine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
| CN103202805B (en) | Vinpocetine-containing pharmaceutical composition for injection and preparation method thereof | |
| CN103393595B (en) | Pharmaceutical composition of edaravone | |
| CN105147602A (en) | Mannitol injection | |
| CN100506804C (en) | Alkyl pyrazine phenolsulfonate and its preparation method and use | |
| CN103961310B (en) | A kind of carbazochrime sodium sulfonate injection and preparation method thereof | |
| CN103393928B (en) | High-capacity pulse-activating injection and preparation method thereof | |
| CN101628022A (en) | Safflower dripping pill and preparation method thereof | |
| CN116211901B (en) | Method for preparing brucea javanica oil composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |